Abstracts tagged "meta-analysis"

Abstract Number: 1502 • ACR Convergence 2025
Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Bisma Shaikh¹, Sarfaraz Hasni² and Omer Pamuk³, ¹Jinnah Sindh Medical University, Karachi, Pakistan, ²NIH/NIAMS, Bethesda, MD, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic disorder characterized by multi-system organ involvement. The hepatic involvement in SLE is categorized as a primary…
Abstract Number: 0258 • ACR Convergence 2025
Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Karyssa Stonick¹, Marcela ferrada², Alice Fike³, Kaitlin Quinn³, Benjamin Turturice³, Casey Stein⁴ and Peter Grayson⁵, ¹National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²University of Maryland, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴NIAMS, NIH, Chevy Chase, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Anti-collagen II (Col2) antibodies have been clinically and experimentally associated with relapsing polychondritis (RP), rheumatoid arthritis (RA), and other diseases. Whether anti-Col2 antibodies are…
Abstract Number: 1476 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
Bana Shawareb¹, Muhannad Haddadin¹, Ansaam Daoud² and Omer Pamuk³, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread immune dysregulation and multi-organ involvement. Autoimmune hemolytic anemia (AIHA), marked by antibody-mediated…
Abstract Number: 0031 • ACR Convergence 2025
Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Alba Boix-Amoros³, Adam Cantor⁴, Jose Scher⁵ and Jose Clemente¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU Langone Health, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴Icahn School of Medicine, New York, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. The sharp increase in prevalence of these disorders over recent decades suggests that factors…
Abstract Number: 1347 • ACR Convergence 2025
The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Aakanksha Pitliya¹, Srivatsa Surya Vasudevan², Sarthak Sharma³, Bijay Mukesh Jeswani⁴, Tanya Ratnani⁵ and Rajesh Thirumaran⁶, ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Louisiana State University Health Sciences Center, Shreveport, LA, ³Government Medical College, Jammu, Jammu, Jammu and Kashmir, India, ⁴GCS Medical College, Hospital and Research Center, Ahmedabad, Gujarat, India, ⁵Chhattisgarh Institute of Medical Sciences, Bilaspur, Chhattisgarh, India, ⁶Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are commonly used disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). While both are widely prescribed,…
Abstract Number: 1222 • ACR Convergence 2025
Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Ahmed Abouelella¹, Mohammad Alhasan², Ahmed Hamoudah³, Ayman Ibrahim⁴, Ola O.A. Abuzied⁵, Mansoor Al-Tamimi⁶ and Muhammed Elhadi⁷, ¹Faculty of Medicine, Benha University, Benha, Al Qalyubiyah, Egypt, ²Health Education England Internal Medicine Training ( Cambridge), Cambridge, United Kingdom, ³Libyan International University, Sarasota, FL, ⁴University of Gezira, Medina, Saudi Arabia, ⁵University of Khartoum, Khartoum, Sudan, ⁶Faculty of Medicine, Cairo University, Cairo, Egypt, ⁷University of Tripoli, Huston, TX
Background/Purpose: Chronic musculoskeletal pain can be a significant source of disability and poor quality of life in adults. Many patients do not achieve adequate relief…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 0670 • ACR Convergence 2025
Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
Zahraa Qamhieh¹, Dalia Sriwi¹, Callie Saric², Tripti Singh³, Christie Bartels⁴ and Shivani Garg⁵, ¹University of Wisconsin, Madison, Department of Medicine, Madison, WI, ²University of Wisconsin, Madison, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, Department of Nephrology, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Clinical response to Mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug monitoring (TDM) of MPA could help improve treatment efficacy. Our objective in…
Abstract Number: 2645 • ACR Convergence 2025
Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
Peter Izmirly¹, Elizabeth Ferucci², Aimee Hersh³, Mary Beth Son⁴, Cristina Drenkard⁵, S. Sam Lim⁶, Cynthia Crowson⁷, Ali Duarte-Garcia⁸, Jill Buyon⁹, Heather Gold⁹, Maria Dall'Era¹⁰, Patti Katz¹¹, Laura Plantinga¹², Jinoos Yazdany¹³, Jennifer Reihm¹⁴, Emily Somers¹⁵ and Hilary Parton¹⁶, ¹New York University Grossman School of Medicine, New York, NY, ²Alaska Native Tribal Health Consortium, Anchorage, AK, ³University of Utah, Salt Lake City, UT, ⁴Boston Children's Hospital, Boston, MA, ⁵Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Mayo Clinic, Stewartvillle, MN, ⁸Mayo Clinic, Rochester, MN, ⁹NYU Grossman School of Medicine, New York, NY, ¹⁰Division of Rheumatology, University of California, San Francisco, CA, ¹¹UCSF, San Rafael, CA, ¹²University of California, San Francisco, San Francisco, CA, ¹³UCSF, San Francisco, CA, ¹⁴University of California, San Francisco, San Francisco, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶New York City Department of Health and Mental Hygiene, New York
Background/Purpose: Current estimates for age of SLE onset are limited, particularly for males and racial/ethnic groups in the United States. Leveraging five Centers for Disease…
Abstract Number: 0845 • ACR Convergence 2025
Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression
Zhiyun Gong¹, Rezvan Parvizi², Helen Jarnagin¹, Haobin Chen³, Madeline Morrisson⁴, Tammara Wood⁵, Monique Hinchcliff⁶, Dinesh Khanna⁷ and Michael Whitfield⁸, ¹Dartmouth College, Lebanon, NH, ²Dartmouth, lebanon, NH, ³Dartmouth Collge, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵Dartmouth, Hanover, NH, ⁶Yale School of Medicine, Westport, CT, ⁷University of Michigan, Ann Arbor, MI, ⁸Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic Sclerosis (SSc) is a clinically and molecularly heterogeneous autoimmune disease. We identified five intrinsic molecular subtypes in SSc by applying semi-supervised machine learning…
Abstract Number: 2643 • ACR Convergence 2025
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
Rahul Bodkhe¹, Kai Trepka¹, Diego Orellana¹, Rebecca Blank², Peter Turnbaugh³, Jose Scher⁴ and Renuka Nayak⁵, ¹University of California San Francisco, San Francisco, CA, ²NYU Langone Health, New York, NY, ³University of California, San Francisco, San Francisco, CA, ⁴New York University School of Medicine, New York, NY, ⁵University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a common systemic autoimmune disease that targets the joints, causing persistent pain and swelling. Oral methotrexate (MTX) remains first-line therapy…
Abstract Number: 0805 • ACR Convergence 2025
Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
Jacquelyn Nestor¹, Zahraa Qamhieh², Shivani Garg³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Wisconsin, Madison, Department of Medicine, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is a foundational therapy in systemic lupus erythematosus (SLE) treatment, as it prolongs disease-free and damage-free survival. However, the optimal dose is…
Abstract Number: 2316 • ACR Convergence 2025
Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores
Gabriela Moreira¹, Hemerli De Cinque Almeida Esteves², Nicole Felix³ and Jose Fernando Verztman¹, ¹Hospital Federal dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ²No current affiliation, Columbus, OH, ³Federal University of Campina Grande, Fortaleza, Ceara, Brazil
Background/Purpose: Beyond musculoskeletal manifestations, there is growing recognition of the systemic and psychosocial burden of axial spondyloarthritis (axSpA). Sexual health is an often-overlooked aspect of…
Abstract Number: 0731 • ACR Convergence 2025
The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Linda Zhu¹, Arielle Mendel², Carolyn Ross³ and Jean-Paul Makhzoum¹, ¹Universite de Montreal, Montreal, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³University of Montreal, Longueuil, Canada
Background/Purpose: The objective of this systematic review is to assess the effectiveness of leflunomide in the treatment of new-onset, refractory or relapsing giant cell arteritis…
Abstract Number: 1194 • ACR Convergence 2024
Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis
Christopher Swearingen¹, Jeyanesh Tambiah² and Yusuf Yazici³, ¹Biosplice Therapeutics, Inc, San Diego, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³NYU Grossman School of Medicine, La Jolla, CA
Background/Purpose: Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways has previously appeared safe, improved patient-reported outcomes (PROs) compared with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].